Genetic Paradox: How Obesity-Causing Mutations May Shield Heart Health
The Two-Faced Nature of Our Genetic Inheritance In the intricate landscape of human genetics, researchers are uncovering surprising dualities that…
Tag: Cardiovascular disease
AI-Powered Stethoscopes: The Next Frontier in Early Disease Detection
Revolutionizing the Iconic Stethoscope with Artificial Intelligence The traditional stethoscope, a symbol of medical practice for nearly two centuries, is…
FDA Approves First Oral GLP-1 Medication for Cardiovascular Risk Reduction in High-Risk Diabetic Patients
** In a landmark decision, the FDA has approved the first oral GLP-1 medication for reducing cardiovascular risk. The approval for Novo Nordisk’s Rybelsus is based on trial data showing a significant reduction in major adverse cardiac events for adults with type 2 diabetes, even without a prior history of heart attack or stroke. **CONTENT:**